[SCHEDULE 13G/A] MoonLake Immunotherapeutics SEC Filing

Rhea-AI Filing Summary

On 08/05/2025 FMR LLC, the parent of Fidelity Investments, together with Abigail P. Johnson, filed Amendment No. 3 to Schedule 13G for MoonLake Immunotherapeutics (MLTX). The filing discloses beneficial ownership of 5,703,048.73 Class A shares (CUSIP 61559X104) as of 06/30/2025, representing 9.0 % of the outstanding class.

The filer reports sole voting power over 5,700,976.70 shares and sole dispositive power over 5,703,048.73 shares; there is no shared voting or dispositive power. The schedule is submitted under Rule 13d-1(b) with FMR classified as a “HC” (parent holding company/control person) and Johnson as “IN” (individual), indicating a passive investment rather than an attempt to influence control. The certification confirms the shares were acquired and are held in the ordinary course of business. No group arrangements, control-changing intentions, or additional financial terms are disclosed.

Positive

• FMR LLC disclosed a 9 % ownership stake, adding reputable institutional backing to MLTX.
• Sole voting and dispositive power over all reported shares provides potential supportive voting bloc for management.

Negative

• None.

Insights

Securities Analyst

TL;DR: Fidelity now owns 9 % of MLTX, signaling strong institutional support but no control intent.

The 13G shows that Fidelity’s parent FMR LLC and Abigail Johnson hold roughly 5.7 million MLTX Class A shares, equal to 9 % of shares outstanding. Because the filing is on Schedule 13G—not 13D—the position is deemed passive. Sole voting and dispositive power suggest Fidelity can act quickly on the stake, yet the certification limits activism. Still, a well-known institution controlling nearly a tenth of the float can enhance liquidity, broaden analyst coverage, and reduce perceived financing risk for MoonLake. Impact is positive but not transformational.

Corporate Governance Expert

TL;DR: Large passive stake raises monitoring but no immediate governance pressure.

The filing clarifies no group formation and no intention to influence control. With sole voting power, Fidelity could vote its 9 % stake on proxy matters, but Schedule 13G suggests it will not pursue activism. Management should nonetheless expect greater scrutiny on performance and ESG factors from a major institutional holder. No red flags appear regarding ownership concentration, as no other single holder exceeds 5 % through Fidelity’s funds.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

MOONLAKE IMMUNOTHERAPEUTICS

(Name of Issuer)

CLASS A COMMON STOCK

(Title of Class of Securities)

61559X104

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 61559X104

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,700,976.70
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,703,048.73
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,703,048.73

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.0 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 61559X104

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,703,048.73
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,703,048.73

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MOONLAKE IMMUNOTHERAPEUTICS
(b)	Address of issuer's principal executive offices: DORFSTRASSE 29,ZUG,V8,6300
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: CLASS A COMMON STOCK
(e)	CUSIP No.: 61559X104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5703048.73
(b)	Percent of class: 9.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 5703048.73
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of MOONLAKE IMMUNOTHERAPEUTICS. No one other person's interest in the CLASS A COMMON STOCK of MOONLAKE IMMUNOTHERAPEUTICS is more than five percent of the total outstanding CLASS A COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	08/05/2025

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson*
Date:	08/05/2025

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

How many MoonLake (MLTX) shares does FMR LLC own?

The filing reports 5,703,048.73 Class A shares, equal to 9 % of the class.

Does FMR LLC have voting control over its MLTX shares?

Yes. It lists sole voting power for 5,700,976.70 shares and no shared voting power.

What form was filed and when?

Amendment No. 3 to Schedule 13G was filed on 08/05/2025 covering holdings as of 06/30/2025.

Is this an activist position?

No. The Schedule 13G classification and certification indicate the stake is passive and held in the ordinary course.

Who signed the Schedule 13G on behalf of FMR LLC?

It was signed by Richard Bourgelas under a power of attorney dated May 23 2023.